RiverPark Advisors LLC Raises Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

RiverPark Advisors LLC increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 94.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,711 shares of the medical equipment provider's stock after purchasing an additional 4,231 shares during the quarter. Intuitive Surgical accounts for 3.2% of RiverPark Advisors LLC's portfolio, making the stock its 6th largest position. RiverPark Advisors LLC's holdings in Intuitive Surgical were worth $4,547,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Dark Forest Capital Management LP increased its stake in shares of Intuitive Surgical by 110.8% in the fourth quarter. Dark Forest Capital Management LP now owns 3,566 shares of the medical equipment provider's stock worth $1,861,000 after purchasing an additional 1,874 shares in the last quarter. Alta Advisers Ltd boosted its stake in Intuitive Surgical by 18.1% during the fourth quarter. Alta Advisers Ltd now owns 1,181 shares of the medical equipment provider's stock worth $616,000 after buying an additional 181 shares during the period. Fayez Sarofim & Co lifted its stake in shares of Intuitive Surgical by 4.4% during the 4th quarter. Fayez Sarofim & Co now owns 1,131,570 shares of the medical equipment provider's stock worth $597,323,000 after acquiring an additional 47,858 shares during the last quarter. J. Safra Sarasin Holding AG grew its stake in Intuitive Surgical by 66.8% in the 4th quarter. J. Safra Sarasin Holding AG now owns 10,409 shares of the medical equipment provider's stock worth $5,433,000 after acquiring an additional 4,168 shares in the last quarter. Finally, OneDigital Investment Advisors LLC grew its holdings in Intuitive Surgical by 0.8% during the 4th quarter. OneDigital Investment Advisors LLC now owns 14,947 shares of the medical equipment provider's stock worth $7,802,000 after acquiring an additional 118 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have commented on ISRG shares. CICC Research started coverage on shares of Intuitive Surgical in a research report on Monday, January 27th. They set a "neutral" rating and a $550.00 price target for the company. Citigroup raised their target price on Intuitive Surgical from $640.00 to $711.00 and gave the stock a "buy" rating in a report on Friday, January 24th. Barclays lowered their price objective on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a research report on Thursday. Raymond James upped their price objective on shares of Intuitive Surgical from $560.00 to $688.00 and gave the stock an "outperform" rating in a research report on Friday, January 24th. Finally, Evercore ISI cut their price objective on Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating for the company in a research note on Wednesday. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, Intuitive Surgical currently has an average rating of "Moderate Buy" and a consensus price target of $598.95.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 11,545 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $499.22, for a total value of $5,763,494.90. Following the sale, the executive vice president now directly owns 5,224 shares in the company, valued at approximately $2,607,925.28. This trade represents a 68.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Brian Edward Miller sold 8,900 shares of the firm's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $485.07, for a total value of $4,317,123.00. Following the transaction, the executive vice president now directly owns 5,758 shares in the company, valued at $2,793,033.06. This trade represents a 60.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 35,454 shares of company stock valued at $18,564,027. 0.70% of the stock is currently owned by corporate insiders.

Intuitive Surgical Trading Up 1.3 %

Shares of NASDAQ ISRG traded up $6.46 during trading on Friday, reaching $514.59. The company had a trading volume of 2,015,889 shares, compared to its average volume of 1,617,024. The stock has a market capitalization of $183.29 billion, a PE ratio of 80.28, a price-to-earnings-growth ratio of 5.85 and a beta of 1.55. The stock has a 50-day moving average price of $511.92 and a two-hundred day moving average price of $532.71. Intuitive Surgical, Inc. has a twelve month low of $367.39 and a twelve month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. Intuitive Surgical had a net margin of 27.81% and a return on equity of 14.55%. The firm had revenue of $2.25 billion during the quarter, compared to the consensus estimate of $2.19 billion. During the same period in the previous year, the firm earned $1.50 earnings per share. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.